

# ASX Announcement

**Melbourne, Australia, 28 April 2023**

## Results of Extraordinary General Meeting

Genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX: EX1) is pleased to advise that shareholders of the Company passed all Resolutions at today's Extraordinary General Meeting by way of poll.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

*By the Managing Director – this announcement has been authorised for release by the Managing Director.*

### [Company and Media Enquiries:](#)

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

[www.exopharm.com](http://www.exopharm.com)

P: +61 (0)3 9111 0026

Ian Dixon  
Managing Director

Tel: +61 418 561 907  
[ian.dixon@exopharm.com](mailto:ian.dixon@exopharm.com)

## ABOUT EXOPHARM

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

Exopharm is also seeking to develop important exosome medicines itself.

## FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.

# Disclosure of Proxy Votes

## Exopharm Limited

General Meeting

Friday, 28 April 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Approval for conversion of Convertible Notes	P	33,683,084	31,360,666 93.11%	77,418 0.23%	0	2,245,000 6.67%	32,486,366 99.76%	77,418 0.24%	0
2 Ratification of prior issue of Options	P	35,866,470	33,542,552 93.52%	78,918 0.22%	0	2,245,000 6.26%	34,668,252 99.77%	78,918 0.23%	0

